Sage Journals: Discover world-class research

Abstract

The cellular factor TRIM5α inhibits infection by numerous retroviruses in a species-specific manner. The TRIM5α protein from rhesus macaques (rhTRIM5α) restricts infection by HIV-1 while human TRIM5α (huTRIM5α) restricts infection by murine leukemia virus (MLV). In owl monkeys a related protein TRIM-Cyp restricts HIV-1 infection. Several models have been proposed for retroviral restriction by TRIM5 proteins (TRIM5α and TRIM-Cyp). These models collectively suggest that TRIM5 proteins mediate restriction by directly binding to specific determinants in the viral capsid. Through their ability to self-associate TRIM5 proteins compartmentalize the viral capsid core and mediate its abortive disassembly via a poorly understood mechanism that is sensitive to proteasome inhibitors. In this review, we discuss TRIM5-mediated restriction in detail. We also discuss how polymorphisms within human and rhesus macaque populations have been demonstrated to affect disease progression of immunodeficiency viruses in these species.

Get full access to this article

View all access options for this article.

References

Bieniasz

. Intrinsic immunity: A front-line defense against viral attack. Nat Immunol, 2004; 5:1109–1115.

Goff

. Retrovirus restriction factors. Mol Cell, 2004; 16:849–859.

Stremlau

et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature, 2004; 427:848–853.

Sayah

et al. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature, 2004; 430:569–573.

Keckesova

et al. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA, 2004; 101:10780–10785.

Perez-Caballero

et al. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol, 2005; 79:8969–8978.

Song

et al. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol, 2005; 79:3930–3937.

Pacheco

et al. Species-specific inhibition of foamy viruses from South American monkeys by New World Monkey TRIM5{alpha} proteins. J Virol, 2010; 84:4095–4099.

Brennan

et al. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci USA, 2008; 105:3569–3574.

10.

Carthagena

et al. Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology, 2008; 5:59.

11.

Diaz-Griffero

et al. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology, 2006; 351:404–419.

12.

Liao

et al. A novel fusion gene, TRIM5-cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS, 2007; 21,Suppl 8:S19–S26.

13.

Newman

et al. Evolution of a TRIM5-CypA splice isoform in Old World monkeys. PLoS Pathog, 2008; 4:e1000003.

14.

Nisole

et al. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci USA, 2004; 101:13324–13328.

15.

et al. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci USA, 2006; 103:7454–7459.

16.

Ylinen

et al. Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J Virol, 2006; 80:7332–7338.

17.

Fletcher

et al. Hare TRIM5alpha restricts divergent retroviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genes. J Virol, 2010; 84:12463–12468.

18.

Schaller

et al. An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 proteins. J Virol, 2007; 81:11713–11721.

19.

Sawyer

et al. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA, 2005; 102:2832–2837.

20.

Song

et al. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol, 2005; 79:6111–6121.

21.

Nisole

et al. TRIM family proteins: Retroviral restriction and antiviral defence. Nat Rev Microbiol, 2005; 3:799–808.

22.

Reymond

et al. The tripartite motif family identifies cell compartments. EMBO J, 2001; 20:2140–2151.

23.

Yamauchi

et al. Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J, 2008; 275:1540–1555.

24.

Diaz-Griffero

et al. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol, 2009; 83:10737–10751.

25.

Perez-Caballero

et al. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol, 2005; 79:15567–15572.

26.

Song

et al. TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology, 2005; 343:201–211.

27.

Campbell

et al. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol, 2008; 180:549–561.

28.

Sastri

et al. Identification of residues within the L2 region of TRIM5α that are required for retroviral restriction and cytoplasmic body localization. Virology, 2010; 405:259–266.

29.

Javanbakht

et al. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology, 2006; 353:234–246.

30.

Mische

et al. Retroviral restriction factor TRIM5alpha is a trimer. J Virol, 2005; 79:14446–14450.

31.

Kar

et al. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J Virol, 2008; 82:11669–11681.

32.

Langelier

et al. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol, 2008; 82:11682–11694.

33.

Javanbakht

et al. The ability of multimerized cyclophilin A to restrict retrovirus infection. Virology, 2007; 367:19–29.

34.

Javanbakht

et al. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem, 2005; 280:26933–26940.

35.

Nepveu-Traversy

et al. TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors. Retrovirology, 2009; 6:100.

36.

, Sodroski

. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol, 2008; 82:11495–11502.

37.

et al. Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha. Virology, 2007; 366:234–244.

38.

Ganser-Pornillos

et al. Hexagonal assembly of a restricting TRIM5{alpha} protein. Proc Natl Acad Sci USA, 2011; 108:534–539.

39.

Stremlau

et al. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol, 2005; 79:3139–3145.

40.

Ohkura

et al. All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. J Virol, 2006; 80:8554–8565.

41.

Yap

et al. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol, 2005; 5:3–8.

42.

Virgen

et al. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci USA, 2008; 105:3563–3568.

43.

Wilson

et al. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci USA, 2008; 105:3557–3562.

44.

Colgan

et al. Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol, 1996; 70:4299–4310.

45.

Franke

et al. Specific incorporation of cyclophilin A into HIV-1 virions. Nature, 1994; 372:359–362.

46.

Forshey

et al. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol, 2005; 79:869–875.

47.

Sebastian

, Luban

. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology, 2005; 2:40.

48.

Stremlau

et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5{alpha} restriction factor. Proc Natl Acad Sci USA, 2006; 103:5514–5519.

49.

Johnson

, Sawyer

. Molecular evolution of the antiretroviral TRIM5 gene. Immunogenetics, 2009; 61:163–176.

50.

Ortiz

et al. Evolutionary trajectories of primate genes involved in HIV pathogenesis. Mol Biol Evol, 2009; 26:2865–2875.

51.

Maillard

et al. The specificity of TRIM5 alpha-mediated restriction is influenced by its coiled-coil domain. J Virol, 2010; 84:5790–5801.

52.

Campbell

et al. TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol Biol Cell, 2007; 18:2102–2111.

53.

Dvorin

, Malim

. Intracellular trafficking of HIV-1 cores: Journey to the center of the cell. Curr Top Microbiol Immunol, 2003; 281:179–208.

54.

Perron

et al. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA, 2004; 101:11827–11832.

55.

Diaz-Griffero

et al. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. J Virol, 2007; 8:32.

56.

Diaz-Griffero

et al. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5{alpha} B-box 2 Domain. J Virol, 2007; 81:10362–10378.

57.

Chatterji

et al. Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem, 2006; 281:37025–37033.

58.

Anderson

et al. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol, 2006; 80:9754–9760.

59.

et al. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA, 2006; 103:7465–7470.

60.

Rold

, Aiken

. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog, 2008; 4:e1000074.

61.

O'Connor

et al.

p62/sequestosome1 associates with and sustains the expression of the retroviral restriction factor TRIM5{alpha}

J Virol, 2010; 84:5997–6006.

62.

Kim

, Ozato

. The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. J Immunol, 2009; 182:2131–2140.

63.

Moscat

et al. Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci, 2007; 32:95–100.

64.

Seibenhener

et al. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol, 2004; 24:8055–8068.

65.

Hwang

et al. Hsp70 interacts with the retroviral restriction factor TRIM5alpha and assists the folding of TRIM5alpha. J Biol Chem, 2010; 285:7827–7837.

66.

Wooten

et al. Essential role of sequestosome 1/p62 in regulating accumulation of Lys63-ubiquitinated proteins. J Biol Chem, 2008; 283:6783–6789.

67.

Kim

et al. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci USA, 2008; 105:20567–20574.

68.

Komatsu

et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol, 2010; 12:213–223.

69.

Pankiv

et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem, 2007; 282:24131–24145.

70.

Sawyer

et al. High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol, 2006; 16:95–100.

71.

Javanbakht

et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology, 2006; 354:15–27.

72.

Goldschmidt

et al. Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology, 2006; 3:54.

73.

van Manen

et al. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog, 2008; 4:e18.

74.

Speelmon

et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol, 2006; 80:2463–2471.

75.

Kirmaier

et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol, 2010; 8.

76.

Lim

et al. TRIM5alpha modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog, 2010; 6:e1000738.

77.

Newman

et al. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci USA, 2006; 103:19134–19139.

78.

Wilson

et al. Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol, 2008; 82:7243–7247.

79.

Ourmanov

et al. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J Virol, 2000; 74:2960–2965.

80.

Polacino

et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol, 1999; 73:618–630.

81.

Yasutomi

et al. Simian immunodeficiency virus-specific CD8 + lymphocyte response in acutely infected rhesus monkeys. J Virol, 1993; 67:1707–1711.

82.

Hirsch

et al. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol, 1997; 71:1608–1620.

Recent Insights into the Mechanism and Consequences of TRIM5α Retroviral Restriction

Abstract

Get full access to this article

References